Citations

Clear

4206 citation(s) found for "Yu, Chen".

C9orf72 poly GA RAN-translated protein plays a key role in amyotrophic lateral sclerosis via aggregation and toxicity
Lee, Youn‐Bok , Baskaran, Pranetha , Gomez-Deza, Jorge, Nishimura, Agnes L. , Smith, Bradley , Troakes, Claire , Adachi, Yoshitsugu, Stepto, Alan, Petrucelli, Leonard , Gallo, Jean‐Marc , Hirth, Frank , Rogelj, Boris , Guthrie, Sarah , Shaw, Christopher E. , Chen, Han-Jou , Troakes, Claire

Mayo Clinic

Human Molecular Genetics | September 11, 2017 | Volume: 26 | Issue: 24 | Pages: 4765-4777

10.1093/hmg/ddx350 | PMID 28973350 Get It

Tokyo Guidelines 2018: management strategies for gallbladder drainage in patients with acute cholecystitis (with videos)
Mori, Yasuhisa , Itoi, Takao , Baron, Todd H. , Takada, Tadahiro , Strasberg, Steven M. , Pitt, Henry A. , Ukai, Tomohiko , Shikata, Satoru , Noguchi, Yoshinori , Kim, Myung‐Hwan , Asbun, Horacio J. , Endo, Itaru , Yokoe, Masamichi, Miura, Fumihiko, Okamoto, Kohji , Umezawa, Akiko , Iwashita, Yukio , Hibi, Taizo , Wakabayashi, Go , Choi, In‐Seok , Hwang, Tsann‐Long , Chen, Miin‐Fu , Garden, O. James , Singh, Harjit , Liau, Kui‐Hin, Huang, Wayne Shih‐Wei, Gouma, Dirk J., Belli, Giulio, Dervenis, Christos, Santibáñes, Eduardo de , Giménez, Mariano , Windsor, John A. , Lau, Wan Yee , Cherqui, Daniel , Jagannath, P., Supe, Avinash , Liu, Keng‐Hao, Su, Cheng‐Hsi, Deziel, Daniel J., Fan, Sheung Tat , Ker, Chen‐Guo , Jonas, Eduard , Padbury, Robert , Sugioka, Atsushi , Asai, Koji , Higuchi, Ryota , Wada, Keita, Yoshida, Masahiro , Mayumi, Toshihiko , Sumiyama, Yoshinobu, Inui, Kazuo, Yamamoto, Masakazu , Teoh, Anthony Yuen Bun , Suzuki, Kenji S. , Han, Ho-Seong , Yoon, Yoo-Seok , Chen, Xiao‐Ping , Mukai, Shuntaro , Honda, Goro , Hirata, Koichi , Jonas, Eduard

Mayo Clinic

Journal of Hepato-Biliary-Pancreatic Sciences | September 9, 2017 | Volume: 25 | Issue: 1 | Pages: 87-95

10.1002/jhbp.504 | PMID 28888080 Get It

Abstract Since the publication of the Tokyo Guidelines in 2007 and their revision in 2013, appropriate management for acute cholecystitis has been more clearly established. Since the last revision, several manuscripts, especially for alternative endoscopic techniques, have been reported; therefore, additional evaluation and refinement of the 2013 Guidelines is required. We describe a standard drainage method for surgically high‐risk patients with acute cholecystitis and the latest developed endoscopic gallbladder drainage techniques described in the updated Tokyo Guidelines 2018 ( TG 18). Our study confirmed that percutaneous transhepatic gallbladder drainage should be considered the first alternative to surgical intervention in surgically high‐risk patients with acute cholecystitis. Also, endoscopic transpapillary gallbladder drainage or endoscopic ultrasound‐guided gallbladder drainage can be considered in high‐volume institutes by skilled endoscopists. In the endoscopic transpapillary approach, either endoscopic naso‐gallbladder drainage or gallbladder stenting can be considered for gallbladder drainage. We also introduce special techniques and the latest outcomes of endoscopic ultrasound‐guided gallbladder drainage studies. Free full articles and mobile app of TG18 are available at: http://www.jshbps.jp/modules/en/index.php?content_id=47 . Related clinical questions and references are also included.
Favorable effects of hydroxychloroquine on serum low density lipid in patients with systemic lupus erythematosus: A systematic review and meta‐analysis
Babary, Hamayon, Liu, Xibei , Ayatollahi, Yosef, Chen, Xin P., Doo, Loomee, Uppaluru, Lakshmi K., Kwak, Myoung Kwan, Kulaga, Catherine, Modjinou, Dodji, Olech, Ewa , Yoo, Ji Won , Yoo, Ji W

Mayo Clinic

International Journal of Rheumatic Diseases | September 8, 2017 | Volume: 21 | Issue: 1 | Pages: 84-92

10.1111/1756-185x.13159 | PMID 28884965 Get It

AbstractAimsHydroxychloroquine (HCQ) has shown to have significant immunomodulatory effects in the treatment of systemic lupus erythematosus (SLE). Current studies show favorable effects of HCQ on traditional cardiac risk factors in patients with SLE. This review examined the effects of HCQ on serum low‐density lipoprotein (LDL) level in patients with SLE.MethodsA systematic search of seven major literature search databases from their inception until 3 April, 2017 identified nine studies. Random‐effects pooled mean difference with corresponding 95% confidence intervals (CI) were estimated. Heterogeneity was measured by I2. Publication bias was assessed by visual inspection of funnel plots. Sensitivity analysis examined whether HCQ effect on serum total cholesterol level was similar to the main analysis. The Grading of Recommendations Assessment, Development, and Evaluation system was used to assess the overall quality of evidence.ResultsPooled study participants were 559 patients from eight observation studies (two before‐after studies; six case‐control studies) examining the effects of HCQ on serum LDL. Pooled study participants' characteristics were as follows: mean age 45.719, female 95.262%, and prednisone use 58.366%. HCQ reduced mean LDL levels by 24.397 mg/dL (95% CI 8.921–39.872; P = 0.002). The number of studies identifying statin use was too few to perform meta‐regression analysis of statin use. Heterogeneity was extensive (I2 = 94.739%). Symmetrical funnel plot visualized no evidence of publication bias.ConclusionHCQ was associated with serum LDL level reduction by mean 24.397 mg/dL in patients with SLE. Future prospective studies are need to fully characterize the treatment effect.
Delphi consensus on bile duct injuries during laparoscopic cholecystectomy: an evolutionary cul‐de‐sac or the birth pangs of a new technical framework?
Iwashita, Yukio , Hibi, Taizo , Ohyama, Tetsuji , Umezawa, Akiko , Takada, Tadahiro , Strasberg, Steven M. , Asbun, Horacio J. , Pitt, Henry A. , Hwang, Tsann‐Long , Choi, In‐Seok , Yoon, Dong Sup , Huang, Wayne Shih‐Wei, Yoshida, Masahiro , Wakabayashi, Go , Miura, Fumihiko, Okamoto, Kohji , Endo, Itaru , Santibáñes, Eduardo de , Giménez, Mariano , Windsor, John A. , Garden, O. James , Gouma, Dirk J., Cherqui, Daniel , Belli, Giulio, Dervenis, Christos, Deziel, Daniel J., Jonas, Eduard , Jagannath, P., Supe, Avinash , Singh, Harjit , Liau, Kui‐Hin, Chan, Angus C. W., Lau, Wan Yee , Fan, Sheung Tat , Chen, Miin‐Fu , Kim, Myung‐Hwan , Sugioka, Atsushi , Asai, Koji , Wada, Keita, Mori, Yasuhisa , Higuchi, Ryota , Misawa, Takeyuki , Matsumura, Naoki , Rikiyama, Toshiki, Kano, Nobuyasu, Tokumura, Hiromi, Kimura, Taizo, Kitano, Seigo, Inomata, Masafumi , Sumiyama, Yoshinobu, Inui, Kazuo, Yamamoto, Masakazu , Han, Ho-Seong , Suzuki, Kenji S. , Yoon, Yoo-Seok , Chen, Xiao‐Ping , Honda, Goro , Watanabe, Manabu , Sata, Naohiro , Hirata, Koichi , Jonas, Eduard

Mayo Clinic

Journal of Hepato-Biliary-Pancreatic Sciences | September 8, 2017 | Volume: 24 | Issue: 11 | Pages: 591-602

10.1002/jhbp.503 | PMID 28884962 Get It

Abstract Bile duct injury ( BDI ) during laparoscopic cholecystectomy remains a serious iatrogenic surgical complication. BDI most often occurs as a result of misidentification of the anatomy; however, clinical evidence on its precise mechanism and surgeons’ perceptions is scarce. Surgeons from Japan, Korea, Taiwan, and the USA, etc. ( n = 614) participated in a questionnaire regarding their BDI experience and near‐misses; and perceptions on landmarks, intraoperative findings, and surgical techniques. Respondents voted for a Delphi process and graded each item on a five‐point scale. The consensus was built when ≥80% of overall responses were 4 or 5. Response rates for the first‐ and second‐round Delphi were 60.6% and 74.9%, respectively. Misidentification of local anatomy accounted for 76.2% of BDI . Final consensus was reached on: (1) Effective retraction of the gallbladder, (2) Always obtaining critical view of safety, and (3) Avoiding excessive use of electrocautery/clipping as vital procedures; and (4) Calot's triangle area and (5) Critical view of safety as important landmarks. For (6) Impacted gallstone and (7) Severe fibrosis/scarring in Calot's triangle, bail‐out procedures may be indicated. A consensus was reached among expert surgeons on relevant landmarks and intraoperative findings and appropriate surgical techniques to avoid BDI .
HPV-related Multiphenotypic Sinonasal Carcinoma
Andreasen, Simon , Hang, Jen‐Fan , Bullock, Martin , Chen, Tiffany , García, Joaquín J. , Gnepp, Douglas R., Gomez‐Fernandez, Carmen , Ihrler, Stephan , Kuo, Ying‐Ju , Lewis, James S. , Magliocca, Kelly R. , Sandison, Ann , Uro‐Coste, Emmanuelle , Stelow, Edward B. , Kiss, Katalin , Westra, William H. , Bishop, Justin A. , Franchi, Alessandro , Pambuccian, Stefan E.

Mayo Clinic

American Journal of Surgical Pathology | September 6, 2017 | Volume: 41 | Issue: 12 | Pages: 1690-1701

10.1097/pas.0000000000000944 | PMID 28877065 Get It

Human papillomavirus (HPV)–related multiphenotypic sinonasal carcinoma (HMSC), originally known as HPV-related carcinoma with adenoid cystic carcinoma-like features, is a peculiar neoplasm that is restricted to the sinonasal tract, exhibits features of both a surface-derived and salivary gland carcinoma (particularly adenoid cystic carcinoma), and is associated with high-risk HPV. Given the limited number of published cases, the full clinicopathologic spectrum of this neoplasm is unclear. Here, we present an updated experience of 49 cases. All cases of HMSC were obtained from the authors’ files. Immunohistochemistry for p16, c-kit, and myoepithelial cell markers (S100, actin, calponin, p63, and/or p40) was performed along with RNA in situ hybridization for HPV (type 33-specific as well as a high-risk cocktail). Fluorescence in situ hybridization studies for fusions ofMYB,NFIB, andMYBL1was performed on a subset of cases. Clinical follow-up was obtained from medical records. A total of 49 cases of HMSC were collected. Twenty-eight (57%) were from women and 18 (43%) from men, ranging in age from 28 to 90 years (mean, 54 y). Of 40 cases with detailed staging information, 43% of HMSCs presented with a high T-stage (T3 or T4). Histologically, most grew predominantly as solid nests of basaloid cells exhibiting high mitotic rates and frequent necrosis, with histologic and immunohistochemical evidence of myoepithelial differentiation. Most cases also demonstrated foci of cribriform and/or tubular growth, along with an inconspicuous population of ducts. Thirty-four (69%) cases demonstrated an unusual pattern of surface involvement where markedly atypical squamous cells colonized tracts of the sinonasal mucosa. Less consistent histologic features included squamous differentiation within the invasive tumor (n=6), sarcomatoid transformation (n=5) including overt chondroid differentiation (n=3), and prominent epithelial-myoepithelial carcinoma-like growth (n=3). All cases were positive for p16 by immunostaining and HPV by RNA in situ hybridization. Thirty-three (67%) were positive for HPV 33. No cases tested forMYB,MYBL1, orNFIBgene fusions were positive. In the 38 cases with follow-up data, (mean follow-up, 42 mo) 14 recurred locally and 2 metastasized (lung, finger). There were no regional lymph node metastases, and no tumor-related deaths. HMSC is a distinct sinonasal neoplasm characterized by myoepithelial differentiation, frequent surface epithelial involvement, and the presence of high-risk HPV (especially type 33). Although it classically exhibits a cribriforming pattern that closely resembles adenoid cystic carcinoma, our expanded series highlights a histologic spectrum that is much broader than previously recognized, warranting a change in terminology. HMSC usually presents as a large and destructive sinonasal mass with high-grade histologic features, but it paradoxically behaves in a relatively indolent manner, underscoring the importance of distinguishing HMSC from true adenoid cystic carcinoma, squamous cell carcinoma, and other histologic mimickers.
Papilloedema and Autoimmune Retinopathy from Systemic Lupus Erythematosus
Chen, John J. , Kumar, Neeraj , McEvoy, Kathleen M., Leavitt, Jacqueline A., Chen, John J

Mayo Clinic

Neuro-Ophthalmology | August 18, 2017 | Volume: 42 | Issue: 2 | Pages: 117-121

10.1080/01658107.2017.1355395 | PMID 29563958 Get It

S100A4 Is a Biomarker and Regulator of Glioma Stem Cells That Is Critical for Mesenchymal Transition in Glioblastoma
Chow, Kin-Hoe, Park, Hee Jung , Yamamoto, Keiko , Gallup, Andrew D., Chen, Yuanxin , Jiang, Wen , Steindler, Dennis A. , Neilson, Eric G. , Kim, Betty Y.S. , Yun, Kyuson , Jiang, Wen , Kim, Betty Y S , George, Joshy , Graber, Joel H.

Mayo Clinic

Cancer Research | August 14, 2017 | Volume: 77 | Issue: 19 | Pages: 5360-5373

10.1158/0008-5472.can-17-1294 | PMID 28807938 Get It

Abstract Glioma stem cells (GSC) and epithelial–mesenchymal transition (EMT) are strongly associated with therapy resistance and tumor recurrence, but the underlying mechanisms are incompletely understood. Here, we show that S100A4 is a novel biomarker of GSCs. S100A4+ cells in gliomas are enriched with cancer cells that have tumor-initiating and sphere-forming abilities, with the majority located in perivascular niches where GSCs are found. Selective ablation of S100A4-expressing cells was sufficient to block tumor growth in vitro and in vivo. We also identified S100A4 as a critical regulator of GSC self-renewal in mouse and patient-derived glioma tumorspheres. In contrast with previous reports of S100A4 as a reporter of EMT, we discovered that S100A4 is an upstream regulator of the master EMT regulators SNAIL2 and ZEB along with other mesenchymal transition regulators in glioblastoma. Overall, our results establish S100A4 as a central node in a molecular network that controls stemness and EMT in glioblastoma, suggesting S100A4 as a candidate therapeutic target. Cancer Res; 77(19); 5360–73. ©2017 AACR.
Assessment of advanced hepatic MR elastography methods for susceptibility artifact suppression in clinical patients
Wang, Jin , Glaser, Kevin J. , Zhang, Tianhui , Shan, Qungang , He, Bingjun , Yin, Meng , Dzyubak, Bogdan , Kugel, Jennifer L., Kruse, Scott A., Grimm, Roger C., Venkatesh, Sudhakar K. , Dzyubak, Bogdan , Venkatesh, Sudhakar K , Yin, Meng , Chen, Jun , Ehman, Richard L.

Mayo Clinic

Journal of Magnetic Resonance Imaging | August 12, 2017 | Volume: 47 | Issue: 4 | Pages: 976-987

10.1002/jmri.25818 | PMID 28801939 Get It

PurposeTo assess the success rate, image quality, and the ability to stage liver fibrosis of a standard 2D gradient‐recalled echo (GRE) and four different spin‐echo (SE) magnetic resonance elastography (MRE) sequences in patients with different liver iron concentrations.Materials and MethodsA total of 332 patients who underwent 3T MRE examinations that included liver fat and iron quantification were enrolled, including 136 patients with all five MRE techniques. Thirty‐four patients had biopsy results for fibrosis staging. The liver stiffness, region of interest area, image quality, and success rate of the five sequences were compared in 115/136 patients. The area under the receiver operating characteristic curves (AUCs) and the accuracies for diagnosing early‐stage fibrosis and advanced fibrosis were compared. The effect of BMI (body mass index), the R2* relaxation time, and fat fraction on the image quality and liver stiffness measurements were analyzed.ResultsThe success rates were significantly higher in the four SE sequences (99.1–100%) compared with GRE MRE (85.3%) (all P < 0.001). There were significant differences of the mean ROI area between every pair of sequences (all P < 0.0001). There were no significant differences in the AUC of the five MRE sequences for discriminating advanced fibrosis (10 P‐values ranging from 0.2410–0.9171). R2* had a significant effect on the success rate and image quality for the noniron 2D echo‐planar imaging (EPI), 3D EPI and 2D GRE (all P < 0.001) sequences. BMI had a significant effect on the iron 2D EPI (P = 0.0230) and iron 2D SE (P = 0.0040) sequences.ConclusionAll five techniques showed good diagnostic performance in staging liver fibrosis. The SE MRE sequences had higher success rates and better image quality than GRE MRE in 3T clinical hepatic imaging.Level of Evidence: 3Technical Efficacy: Stage 5J. Magn. Reson. Imaging 2018;47:976–987.
Quantifying the Effects of Prior Acetyl-Salicylic Acid on Sepsis-Related Deaths: An Individual Patient Data Meta-Analysis Using Propensity Matching*
Trauer, James M. , Muhi, Stephen , McBryde, Emma S. , Harbi, Shmeylan Al, Arabi, Yaseen M. , Boyle, Andrew , Cartin‐Ceba, Rodrigo , Chen, Yung‐Tai , Gajić, Ognjen, Godsell, Jack , Gong, Michelle N. , Kor, Daryl J. , Lösche, Wolfgang, McAuley, Daniel F. , O’Neal, Hollis R. , Otto, Gordon P , Soßdorf, Maik, Tsai, Min-Juei, Valerio-Rojas, Juan Carlos , Poll, Tom van der , Ware, Lorraine B. , Widmer, Andreas F. , Wiewel, Maryse A. , Winning, Johannes, Eisen, Damon P. , Trauer, James, Harbi, Shmeylan A. Al , Chen, Wei, Falcone, Marco , Gajic, Ognjen , Osthoff, Michael Friedrich , Violi, Francesco , Arabi, Yaseen M

Mayo Clinic

Critical Care Medicine | August 10, 2017 | Volume: 45 | Issue: 11 | Pages: 1871-1879

10.1097/ccm.0000000000002654 | PMID 28799949 Get It

Objective: The primary objective was to conduct a meta-analysis on published observational cohort data describing the association between acetyl-salicylic acid (aspirin) use prior to the onset of sepsis and mortality in hospitalized patients. Study Selection: Studies that reported mortality in patients on aspirin with sepsis with a comparison group of patients with sepsis not on prior aspirin therapy were included. Data Sources: Fifteen studies described hospital-based cohorts (n = 17,065), whereas one was a large insurance-based database (n = 683,421). Individual-level patient data were incorporated from all selected studies. Data Extraction: Propensity analyses with 1:1 propensity score matching at the study level were performed, using the most consistently available covariates judged to be associated with aspirin. Meta-analyses were performed to estimate the pooled average treatment effect of aspirin on sepsis-related mortality. Data Synthesis: Use of aspirin was associated with a 7% (95% CI, 2–12%; p = 0.005) reduction in the risk of death as shown by meta-analysis with considerable statistical heterogeneity (I 2 = 61.6%). Conclusions: These results are consistent with effects ranging from a 2% to 12% reduction in mortality risk in patients taking aspirin prior to sepsis onset. This association anticipates results of definitive studies of the use of low-dose aspirin as a strategy for reduction of deaths in patients with sepsis.